CADL (Candel) Cumulative Company Assets

Official company branding of Candel Therapeutics (CADL)

Candel Therapeutics (CADL) is developing the CAN-2409 platform to eliminate solid tumors, leveraging FDA support and interest from major pharma behemoths. This share price chart featuring the 157.05 metric reflects the asset dynamics. Candel Therapeutics (CADL) targets the treatment of prostate and brain cancer, relying on payments from government funds. However, a high dependency on final test outcomes and the risk of funding shortages pose a serious threat to capital.

Candel Therapeutics (CADL) Aggregate Company Assets: for the period 07/04/2022 - 10/30/2026

Financial and market metric breakdowns for candeltx.com (CADL)

- share price and consensus valuation forecast:
Price Chart Candel Therapeutics, Inc.|CADL - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Candel Therapeutics, Inc.|CADL - Enterprise Value
- company book value details:
Book Value per Share Candel Therapeutics|CADL - Company Book Value|Capitalization to Book Value Ratio candeltx.com|CADL - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Candel Therapeutics|CADL - Long-Term Debt to Capital|Current Liabilities to Capital Candel Therapeutics, Inc.|CADL - Company Debts|Debt to Net Assets Ratio Candel Therapeutics, Inc.|CADL - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Candel Therapeutics|Quick Liquidity Indicator candeltx.com
- earnings and market multiples details:
CADL - Net Income
Basic company analysis:Candel (CADL)
Core merchandise of Candel Therapeutics

The volume of capital allows for the separation of a fundamentally resilient business from speculative assets. The high scientific competence of Candel Therapeutics (CADL) management in oncology guarantees the targeted allocation of resources. By analyzing the trends of the company's total assets, calculated inversely via ROA, an investor can see the aggregate value of assets and liabilities. Growth in this metric confirms financial stability, provided it is accompanied by an effective return on investment.

Key competitors

ONC (beigene.com) - Aggregate Company Assets|HALO (Halozyme) - Company Total Assets|Cumulative Company Assets Revolution Medicines Inc (RVMD)|Company Total Assets AAPG|Company Total Assets CG Oncology Therapeutics (CGON)|Aggregate Company Assets UroGen Pharma Ltd. URGN|BCAX: Total Business Assets|Personalis - Company Total Assets|Erasca Inc (ERAS) - Cumulative Company Assets|DCTH: Company Total Assets|Company Assets Y-mAbs Corp (YMAB)|Aggregate Company Assets Aura Biosciences, Inc.|ARAY: Aggregate Asset Value|Cumulative Company Assets SLS (SELLAS Life Sciences)|ACTU (Actuate Therapeutics Inc.) - Aggregate Asset Value|Company Total Assets CTOR (Citius Oncology, Inc)|HURA - Cumulative Company Assets|TARA: Cumulative Company Assets|FATE - Company Total Assets|aadibio.com (WHWK) - Aggregate Company Assets|TScan Therapeutics, Inc. - Aggregate Asset Value|CSBR (Champions Oncology Inc) - Company Total Assets|Company Assets XBiotech USA XBIT|Company Total Assets CVM|Cumulative Company Assets ostherapies.com OSTX|Company Total Assets RADX (Radiopharm Theranostics)|Company Total Assets Artiva Biotherapeutics Inc. ARTV|ANL - Aggregate Company Assets|VERU (Veru Corporation) - Total Business Assets|TPST: Company Total Assets|Total Business Assets XLO|RENB (Renovaro Biosciences) - Company Total Assets|Company Assets Mural Bio MURA|Aggregate Company Assets Kairos Pharma Ltd (KAPA)|Aggregate Company Assets OKUR (onkuretherapeutics.com)|CytoMed Therapeutics Limited - Cumulative Company Assets|Aggregate Asset Value CRIS|APLM: Cumulative Company Assets|Tharimmune Inc - Aggregate Business Assets|ADVB: Company Total Assets|Genprex Inc - Aggregate Asset Value|CLDI (Calidi Biotherapeutics Inc.) - Company Total Assets|Company Assets sunshinebiopharma.com SBFM|Aggregate Company Assets Xenetic Biosciences (XBIO)|SLRX (Salarius Pharmaceuticals Inc) - Aggregate Asset Value|Company Total Assets PPBT (Purple Biotech Corp)|Company Total Assets American Oncology Network Inc AONC|BGNE - Aggregate Company Assets|Total Asset Value of Company CKPT|ELEV: Company Total Assets|Company Assets iCAD (ICAD)|Cumulative Company Assets IKNA|Company Total Assets Notable Labs Corp|Cumulative Company Assets VIRX (Viracta Therapeutics)|Aggregate Business Assets MOR|Company Total Assets NAYA (NAYA Biosciences Inc.)|Company Total Asset Base Ascentage Pharma Group International (AAPGV)